TEVA Teva- Pharmaceutical Industries Ltd

  1. Stocks
  2. Healthcare
  3. NYSE: TEVA

Price (delayed)

$43.75

Market cap

$51.05B

P/E Ratio

97.22

Dividend/share

N/A

EPS

$0.45

Enterprise value

$63.95B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 49

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic ...

Highlights
TEVA's quick ratio is up by 11% from the previous quarter
Teva- Pharmaceutical Industries's equity has increased by 10% YoY and by 2.9% QoQ
The price to earnings (P/E) is 103% higher than the last 4 quarters average of 47.3
Teva- Pharmaceutical Industries's EPS has decreased by 29% QoQ and by 29% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.tevapharm.com
Peers: NVS PFE MRK AZN

Key stats

What are the main financial stats of TEVA

TEVA stock price

How has the Teva- Pharmaceutical Industries stock price performed over time
Intraday
1.18%
1 week
4.72%
1 month
6.27%
1 year
69.38%
YTD
40.18%
QTD
10.48%

Financial performance

How have Teva- Pharmaceutical Industries's revenue and profit performed over time
Revenue
$17.23B
Gross profit
$9.22B
Operating income
$1.34B
Net income
$506M
Gross margin
53.5%
Net margin
2.9%
The net margin has declined by 31% year-on-year and by 29% since the previous quarter
The operating margin fell by 29% YoY and by 15% QoQ
TEVA's net income is down by 29% year-on-year and by 28% since the previous quarter
TEVA's operating income is down by 28% YoY and by 15% from the previous quarter

Price vs fundamentals

How does TEVA's price correlate with its fundamentals

Growth

What is Teva- Pharmaceutical Industries's growth rate over time

Valuation

What is Teva- Pharmaceutical Industries stock price valuation
P/E
97.22
P/B
6.39
P/S
2.96
EV/EBIT
44.29
EV/EBITDA
26.33
EV/Sales
3.71
The price to earnings (P/E) is 103% higher than the last 4 quarters average of 47.3
Teva- Pharmaceutical Industries's EPS has decreased by 29% QoQ and by 29% YoY
TEVA's price to book (P/B) is 143% higher than its 5-year quarterly average of 2.6 and 29% higher than its last 4 quarters average of 4.9
Teva- Pharmaceutical Industries's equity has increased by 10% YoY and by 2.9% QoQ
The P/S is 144% above the 5-year quarterly average of 1.2 and 27% above the last 4 quarters average of 2.3
TEVA's revenue is up by 2.7% year-on-year

Efficiency

How efficient is Teva- Pharmaceutical Industries business performance
TEVA's ROE is down by 42% YoY and by 30% from the previous quarter
Teva- Pharmaceutical Industries's return on assets has decreased by 28% QoQ and by 28% YoY
Teva- Pharmaceutical Industries's return on sales has decreased by 25% YoY and by 10% QoQ
The company's return on invested capital fell by 10% YoY and by 5% QoQ

Dividends

What is TEVA's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history

Special dividends are included in TTM DPS and yield

Financial health

How did Teva- Pharmaceutical Industries financials performed over time
The total assets is 25% greater than the total liabilities
Teva- Pharmaceutical Industries's current ratio has decreased by 14% YoY but it has increased by 8% QoQ
TEVA's quick ratio is up by 11% from the previous quarter
The debt is 113% greater than the equity
Teva- Pharmaceutical Industries's equity has increased by 10% YoY and by 2.9% QoQ
TEVA's debt to equity is down by 9% YoY and by 2.3% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.